Annual report pursuant to Section 13 and 15(d)

2. Summary of Significant Accounting Policies (Details Narrative)

v3.20.1
2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Jun. 25, 2019
Dec. 31, 2019
Dec. 31, 2018
Basis Of Presentation And Significant Accounting Policies [Line Items]      
Reverse stock split 1-for-12 reverse stock split    
Letter of credit   $ 0 $ 100,000
Letter of credit purpose     Lexington Lease
Impairment of long-lived assets   0 $ 0
Accrued expenses and other current liabilities   484,029 665,641
Prepaid expenses and other   $ 722,079 $ 555,856
Antidilutive shares   516,000 65,000
JSOP [Member]      
Basis Of Presentation And Significant Accounting Policies [Line Items]      
Awards outstanding   27,000 27,000
Accrued Program Expense [Member]      
Basis Of Presentation And Significant Accounting Policies [Line Items]      
Accrued expenses and other current liabilities   $ 100,000 $ 200,000
Deposits held with clinical trial vendors [Member]      
Basis Of Presentation And Significant Accounting Policies [Line Items]      
Prepaid expenses and other   $ 700,000 $ 700,000